Today’s Top Three in Pharma 022709

Prasugrel – the saga continues. Gets approval to launch in the EU; positive study results versus Plavix for a certain group of patients; but controversy swirls around FDA approval process.
Synta’s Phase III trial for melanoma drug fails badly. In a devastating blow to the company, Synta Pharmaceuticals has halted a Phase III melanoma drug trial after [...]

Read Full Post »

Today’s Top Three in Pharma 022509

Sales force efficiency (revenue generated per sales rep) measured and reported among 20 pharma companies – who do you think is on top? Plus, PWC issues a report with a keen grasp of the obvious about targeted (vs. mass) sales forces in the future.
Onyx: Good news! Another reported loss! (OK, sales of Nexavar are strong…)
Baldness [...]

Read Full Post »

Today’s Top Three in Pharma 022409

Merck has laid off 750 sales reps so far this year. Ouch.
Genentech to Roche: No. Again (translation: move us from “no” with “dough”…)
Endo brings Indevus into the fold.
PLUS – who is actively involved in social media in pharma? I’m assembling a growing list…here’s what we have so far on this expanding community.
——
Subscribe to the Impactiviti [...]

Read Full Post »

Today’s Top Three in Pharma 022309

The Skinny on Diabetes Drugs – a helpful little summary on current treatments from the Motley Fool.
Beaker’s Blog tells us that only 4 life sciences companies really matter. Who are they, and why?
Astellas continues to pursue CV Therapeutics after takeover bid rejected.
——
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with [...]

Read Full Post »

More Pharma eMarketing stuff

John Mack at Pharma Marketing blog discusses the downturn in marketing spend.
Newly discovered (by me, anyway!) blog on pharma eMarketing: Dose of Digital. Some interesting recent posts – FDA Uses Social Media, but You Can’t | Gaming to Save Healthcare Marketing | The Myth of Adverse Event Reporting
And, here’s my take on the dance of [...]

Read Full Post »

Today’s Top Three in Pharma 022009

Genentech’s Raptiva: Trouble – The FDA said today that patients taking the Genentech drug Raptiva are at risk of developing a potentially fatal condition known as PML, or progressive multifocal leukoencephalopathy. The drug’s label already carried a warning about this possibility. But last week, Genentech sent a letter to alert doctors that a third case [...]

Read Full Post »

After Hours 022009

Endless Interestingness – an endless collage of images pulled from Flickr. Cool idea. Hat tip: Guy Kawasaki.
The Crisis of Credit visualized. What happened to our financial markets? This simple, entertaining, and informative animation explains the blow up. Well worth a few minutes of your time. Hat tip: David Armano.
The “blog” of “unnecessary” quotation marks. Fun [...]

Read Full Post »

Training Need: Follow-up/Reinforcement

The training event has happened. And now you’re left wondering – will they remember it? Will the learning be applied? How can this be reinforced over time?
We can help.
Impactiviti’s Preferred Partner network includes a company with a uniquely useful offering – a template-driven tool that allows you to create mini-scenarios (1-3 minutes), which can be [...]

Read Full Post »

A Handful of Training Trends

I was recently asked, by a pharmaceutical client, what was “new” and leading-edge in training.
I haven’t seen a lot of specific programs or approaches that struck me as the latest-and-greatest must-haves, but there are certain social and technology trends that will profoundly impact training in the years to come. Here are a handful that I [...]

Read Full Post »

Today’s Top Three in Pharma 021909

Teva aggressively seeking to “genericize” Merck’s Singulair, Amgen’s Neupogen.
Warren Buffet pulling back from pharma investments that contain 2 letters (P&G, J&J).
GSK’s nausea drug Zofran may help with drug withdrawal symptoms – GlaxoSmithKline Plc’s Zofran, approved to treat nausea and vomiting, appears to reduce symptoms of withdrawal from morphine, codeine, heroin, OxyContin and similar pain medicines, [...]

Read Full Post »